No price history available.
Key financial summary
Financials in MYR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | MYRm | 2,725 | 4,815 | 3,481 | 3,404 | 3,759 | 3,928 | N/A | N/A |
| Operating profit | MYRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | MYRm | 27 | 172 | -630 | -80 | 132 | 49 | N/A | N/A |
| EPS reported | MYR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | MYR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | MYR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | MYR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | MYRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | MYRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | MYRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | MYR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | MYR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in MYR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Pharmaniaga Berhad operates as an investment holding company and an integrated pharmaceutical entity across Malaysia, Indonesia, and international territories. The company organizes its operations into three main segments: Logistics and Distribution, Manufacturing, and its Indonesian business unit. Its core activities encompass the production, distribution, trading, wholesaling, and marketing of a wide array of pharmaceutical and medical products. Additionally, Pharmaniaga is involved in the procurement, sale, and installation of medical and hospital equipment, as well as the trading and wholesaling of consumer goods. The company's offerings also include the manufacturing and sale of generic and over-the-counter medicines, coupled with research and development efforts for pharmaceutical products. It further engages in the production, distribution, trade, and sale of food supplements, alongside the distribution and trading of diagnostic products. Under its RoyalePharma brand, the company also manages community pharmacies. Founded in 1994, Pharmaniaga Berhad is headquartered in Shah Alam, Malaysia, and functions as a subsidiary of Boustead Holdings Berhad.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Pharmaniaga Berhad operates as an investment holding company and an integrated pharmaceutical entity across Malaysia, Indonesia, and international territories. The company organizes its operations into three main segments: Logistics and Distribution, Manufacturing, and its Indonesian business unit. Its core activities encompass the production, distribution, trading, wholesaling, and marketing of a wide array of pharmaceutical and medical products. Additionally, Pharmaniaga is involved in the procurement, sale, and installation of medical and hospital equipment, as well as the trading and wholesaling of consumer goods. The company's offerings also include the manufacturing and sale of generic and over-the-counter medicines, coupled with research and development efforts for pharmaceutical products. It further engages in the production, distribution, trade, and sale of food supplements, alongside the distribution and trading of diagnostic products. Under its RoyalePharma brand, the company also manages community pharmacies. Founded in 1994, Pharmaniaga Berhad is headquartered in Shah Alam, Malaysia, and functions as a subsidiary of Boustead Holdings Berhad.